Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 10

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 10
---
itation of proxies for our 2026 Annual Meeting of Stockholders. Stockholders may obtain our proxy statement (and any amendment and supplements thereto) and other documents as and when we file them with the SEC on the “Investor Relations” section of the Company’s website atinvestor.an2therapeutics.comor on the SEC’s website atwww.sec.gov.

How may I obtain AN2 Therapeutic’s Form 10-K and other financial information?

Stockholders can access our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”), which contains financial information about the Company, on the “Investor Relations” section of the Company’s website atinvestor.an2therapeutics.comor on the SEC’s website atwww.sec.gov. Alternatively, current and prospective investors may request a free copy of our Annual Report from:

<div align='center'>AN2 Therapeutics, Inc.

1800 El Camino Real, Suite D

Menlo Park, California 94027

Attn: Corporate Secretary</div>

We also will furnish any exhibit to the Annual Report if specifically requested upon payment of charges that approximate our cost of reproduction. The website addresses in this proxy statement are included for reference only. The information contained on these websites is not incorporated by reference into this proxy statement.

<div align='center'>5</div>

DIRECTORS AND C ORPORATE GOVERNANCE Board Composition Our business affairs are managed under the direction of our Board, which is currently composed of nine members. Our directors are divided into three classes serving staggered three year terms. Upon expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three year term at the annual meeting of stockholders in the year in which their term expires. As a result of this classification of directors, it generally takes at least two annual meetings of stockholders for stockholders to effect a change in a majority of the members of our Board. The names, ages, principal occupations and certain other information about the director nominees with terms expiring at the Annual Meeting and the additional members of our Board as of March 24, 2025 (including the skills and qualifications that led to the conclusion that they should serve as directors) are set forth below.

| Name                         | ﻿ | Position(s)                                        |     | Age |
| Nominees:                    | ﻿ | ﻿                                                  |     |   ﻿ |
| Eric Easom                   | ﻿ | President, Chief